NL-OMON52602招募中不适用
Reducing fatigue in visually impaired adults with E-nergEYEze: An RCT to assess the cost-effectiveness of a blended vision-specific E-health based cognitive behavioral & self-management intervention. - E-nergEYEze
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 187
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •- visually impaired according to WHO criteria + guidelines of rehabilitation
- •center, of any cause (eye condition); moderate visual impairment or worse and,
- •in consultation with the research team, a progressive mild visual impairment.
- •- 18 years or older
- •- understanding of the Dutch language
- •- experiencing severe fatigue (CIS-score>35)
- •- having home access to internet
排除标准
- •- severe cognitive limitations assessed with the 6-item screener (short
- •validated Mini Mental State Examination).
- •- currently receiving treatment, or having received treatment in the last 12
- •months for comorbid disease that clearly is the main cause of fatigue (e.g. MS,
- •cancer, psychiatric disorder).
研究者
相似试验
已完成
3 期
E-nergEYEze, a vision-specific eHealth intervention based on cognitive behavioral therapy and self-management to reduce fatigue in adults with visual impairment<tr><td>People with a visual impairment and in the experience of severe fatigue</td></tr>Fatigue, Visual impairment, Cognitive behavioral therapy, Self-management, eHealth, Randomized controlled trial10047518NL-OMON28085Amsterdam University Medical Centres172
尚未招募
不适用
Verification of eye fatigue suppression effect by ingesting test foods. A placebo-controlled, Simple Randomization, open, cross over trial.healthy adultJPRN-UMIN000031400otte Co., Ltd.10
已完成
不适用
Verification of eye fatigue suppression effect by ingesting test foods. A placebo-controlled, Simple Randomization, double blind, cross over trial.healthy adultJPRN-UMIN000037406School of Allied Health Sciences, Kitasato University50
已完成
不适用
Objective determine visual fatigueJPRN-UMIN000021964Osaka university100
进行中（未招募）
不适用
Prevention of vision loss in patients with age-related neovascular macular degeneration by intravitreal injection of bevacizumab and ranibizumab in a typical outpatient setting - VIBERAEUCTR2007-004721-23-DEKlinikum Bremen-Mitte gGmbH